Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
63 hedge funds and large institutions have $15.6M invested in Seelos Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 16 closing their positions.
63% more call options, than puts
Call options by funds: $791K | Put options by funds: $484K
7% less funds holding
Funds holding: 68 → 63 (-5)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
44% less capital invested
Capital invested by funds: $28M → $15.6M (-$12.4M)
75% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$792K |
| 2 |
SFWC
Strategic Family Wealth Counselors
Fairfield,
New Jersey
|
+$94.2K |
| 3 |
Mariner
Overland Park,
Kansas
|
+$48.8K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$45.3K |
| 5 |
VF
Virtu Financial
New York
|
+$31.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$1.19M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$795K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$720K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$478K |
| 5 |
E
Ergoteles
New York
|
-$416K |
SEEL Hedge Fund Activity: Q4 2022 in Review
63 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2022, worth a combined $15.6M — down 44% from $28M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SEEL and 11 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 4 added.
The largest buyer was Modera Wealth Management, opening a new position worth an estimated $792K. The largest seller was Uniplan Investment Counsel, cutting an estimated $1.19M.
- 63 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2022, down from 68 in Q3 2022.
- Funds reported $15.6M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2022, down 44% quarter-over-quarter.
- 11 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2022 and 16 closed out, a net change of -5 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2022 was Modera Wealth Management, an estimated $792K added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2022 was Uniplan Investment Counsel, an estimated $1.19M sold.
Based on aggregated 13F filings for Q4 2022.